TABLE 1.
Summary of patients who received at least three days of intravenous colistin (COL) from 2000 to 2005
| Patient | MBL* | Age, years | Site of care | Susceptibility profile of organism | Days on COL (n) | Infection |
COL base equivalent |
Outcome | ME | Creatinine increase (%) | Other adverse effects | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regimen | mg/kg/day† | |||||||||||
| 1 | Yes | 33 | ICU | Empirical | 18.4 | PNU2 | 100 mg q8h | 4.6 | Ind, died | Yes | 30 | Diarrhea |
| 2 | No | 66 | LTC | S: CAZ
R: PIP, TZP, AG, CIP |
5.8 | SUTI
– |
75 mg q8h
50 mg q8h |
2.9 | U, died | Yes | 141 | |
| 3 | Yes | 49 | HD | S: COL
R: PIP, TZP, CAZ, FEP, AZT, AG, CIP |
8.8 | BONE
– |
80–85 mg
post-HD |
N/A | F, home | No | N/A | |
| 4 | Yes | 61 | ONC | S: PIP, TZP, AZT, COL
R: AG, CIP; I: FEP |
8.5 | LCBI | 150 mg q36h | N/A | F, home | Yes | 15 | Neurotoxicity |
| 5 | No | 21 | AMB | S: PIP, CAZ, IPM; I: AZT | 46.0 | SUTI | 50 mg q8h | 2.9 | Ind, home | No | N/A | – |
| 6 | Yes | 51 | ONC | S: PIP, TZP, AZT, COL
R: CAZ, AG, CIP |
7.9 | LCBI | 100 mg q6h
75 mg q8h |
5.3 | U, died | Yes | 143 | Neurotoxicity, GI |
| 7 | Yes | 80 | GEN | S: COL
I: AZT R: PIP, TZP, FEP, CAZ, AG, CIP |
4.7 | SUTI | 75 mg q8h | 4.2 | F, home | Yes | 170 | Drug fever, anorexia, nausea |
| 8 | Yes | 47 | GEN | I: COL
R: PIP, TZP, CAZ, AG, CIP |
9.6 | SUTI | 50 mg q8h
75 mg q8h |
2.8 | F, home | No | 319 | Neurotoxicity, drug interaction |
| 9 | No | 49 | AMB | Empirical | 38.0 | SUTI | 50 mg q8h
50 mg q12h |
2.1 | F, home | Yes | N/A | Anorexia, myalgia |
| 10 | Yes | 55 | ONC | S: PIP, AZT, COL
R: CAZ, AG, CIP |
5.6 | LCBI | 75 mg q12h | 2.7 | F, home | Yes | 1.5 | Nausea |
| 11 | Yes | 64 | ICU | S: TZP, AZT, COL
R: AG, CIP |
3.7 | PNU1 | 75 mg q8h | 3.5 | F, home | Yes | 19 | – |
| 12 | Yes | 46 | ICU | S: COL
R: PIP, CAZ, AG, CIP |
19.7 | PNU2 | 125 mg q6h | 6.0 | F, home | Yes | 100 | Neurotoxicity |
Metallo-beta-lactamase (MBL)-producing Pseudomonas aeruginosa (resistant to imipenem [IPM] and meropenem). The most frequently encountered minimum inhibitory concentrations were as follows – piperacillin (PIP) 32 μg/mL (susceptible [S]), PIP/tazobactam (TZP) 16 μg/mL (S), ceftazidime (CAZ) 32 μg/mL (resistant [R]), cefepime (FEP) 16 μg/mL (intermediate [I]), aztreonam (AZT) 8 μg/mL (S), gentamicin greater than 128 μg/mL (R), tobramycin greater than 128 μg/mL (R), amikacin 64 μg/mL (R), ciprofloxacin (CIP) 64 μg/mL (R);
Using ideal/lean body weight. AG Aminoglycosides; AMB Ambulatory outpatient; BONE Osteomyelitis; F Favourable; GEN General ward; GI Gastrointestinal; HD Hemodialysis; Home Discharged home; ICU Intensive care unit; Ind Indeterminate; LCBI Laboratory-confirmed bloodstream infection; LTC Long-term care unit; ME Microbiological eradication; N/A Not available or not applicable; ONC Hematology/stem cell transplant unit; PNU1 Clinically defined pneumonia; PNU2 Pneumonia and specific laboratory findings; q Every; SUTI Symptomatic urinary tract infection; U Unfavourable